Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced it will present at Point-of-Care Testing 2025 in Boston on Dec. 9, 2025. The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will describe the company's move to portable PCR devices, the upcoming Co-Dx PCR platform (including Co-Dx PCR Home and Co-Dx PCR Pro), an intuitive smartphone interface, and the integration of AI to reduce user error and improve real-time point-of-care outcomes.

The speaker session is scheduled for 11:30 AM EST at the Boston Marriott Cambridge. The summary notes the Co-Dx PCR platform and associated tests/software remain subject to FDA and other regulatory review and are not available for sale.

Key Figures

Presentation time 11:30 AM EST Point-of-Care Testing 2025 conference session in Boston

Market Reality Check

$0.3627 Last Close

Volume Volume 1,928,762 is 8% above the 20-day average of 1,778,924. normal

Technical Trading slightly below the 200-day MA of 0.35 after a -7.37% session.

Peers on Argus 1 Up 1 Down

CODX fell 7.37% while several close peers like AIMD (-7.17%) and XAIR (-5%) were also down, though momentum data show mixed moves with SINT up 4.75% and PAVM down 4.47%, pointing to stock- and micro-cap risk factors rather than a clean sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 20	TB test update	Positive	-5.8%	Highlighted upcoming MTB PoC test and potential expansion into India and South Africa.
Nov 18	Clinical evaluations	Positive	+13.4%	Initiated clinical evaluations for upper respiratory multiplex test to support FDA 510(k).
Nov 13	Q3 2025 earnings	Negative	-6.1%	Reported sharp revenue decline, operating loss, and reliance on recent financings.
Nov 12	JV recognition	Positive	+0.7%	Recognition by Utah leadership following CoMira JV announcement in Saudi Arabia.
Nov 05	SPAC exploration	Positive	+3.5%	Engaged Maxim Group to explore SPAC or similar transaction for CoSara JV.

Pattern Detected

Recent news has often been met with weak or negative reactions, including on earnings and positive commercial/clinical updates.

Recent Company History

Over the last month, CODX has reported Q3 2025 results with low $0.1M revenue and ongoing losses, pursued regional expansion via JVs in Saudi Arabia and MENA, and advanced its Co-Dx PCR platform through clinical evaluations and tuberculosis test plans. AI integration and point-of-care positioning have been recurring themes. Price reactions have been mixed, with both gains and selloffs following ostensibly positive operational updates.

Market Pulse Summary

This announcement emphasizes CODX’s focus on a portable, cloud-connected Co-Dx PCR platform and AI-driven interface to reduce user error at point-of-care. It builds on prior communications about AI integration and multiplex testing on the same platform, which is still under regulatory review and not yet for sale. Investors may watch for future updates on FDA and other regulatory submissions, clinical performance data, and how these technologies translate into revenue growth and funding stability.

Key Terms

pcr medical

"Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

ai technical

"discuss how Co-Dx is harnessing AI to minimize user error"

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

fda regulatory

"subject to review by the FDA and/or other regulatory bodies"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA.

The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will unpack Co-Dx's move to portable PCR diagnostics to address evolving point-of-care needs, introduce the Company's upcoming Co-Dx PCR platform* and intuitive smartphone interface, and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.

The Conference provides a forum for industry leaders and healthcare innovators to explore the latest breakthroughs in diagnostic testing, advanced technologies, and clinical strategies driving the future of patient-centered care. Agenda topics include trends in point-of-care diagnostics and patient-centered care strategies, innovative platforms for mobile testing and real-time health monitoring, the integration of AI and digital platforms in next-generation diagnostics, and advanced testing kits for infectious and chronic disease management.

The speaker session will be held at 11:30 AM EST at the Boston Marriott Cambridge in Massachusetts.

*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-present-on-co-dx-pcr-platform-and-ai-integration-at-point-of-care-testing-2025-302636360.html

SOURCE Co-Diagnostics

FAQ

When will Co-Diagnostics (CODX) present at Point-of-Care Testing 2025?

Co-Diagnostics will present on Dec. 9, 2025 at 11:30 AM EST at the Boston Marriott Cambridge.

What is the title of Co-Diagnostics' (CODX) presentation at the conference?

The presentation is titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics".

What products will Co-Diagnostics (CODX) discuss at Point-of-Care Testing 2025?

Co-Diagnostics will introduce its upcoming Co-Dx PCR platform, including Co-Dx PCR Home, Co-Dx PCR Pro, the mobile app, and associated tests and software.

How is Co-Diagnostics (CODX) integrating AI into its Co-Dx PCR platform?

Co-Diagnostics will discuss using AI to minimize user error and improve real-time point-of-care outcomes.

Is the Co-Dx PCR platform from Co-Diagnostics (CODX) available for sale now?

No. The Co-Dx PCR platform and associated tests/software are subject to FDA and other regulatory review and are not available for sale.